目的 对2014—2016年南京地区34家医院质子泵抑制剂的使用情况进行统计分析，以了解其临床使用趋势和是否合理。方法 对2014—2016年南京地区34家医院质子泵抑制剂的规格、数量、销售金额、用药频度（DDDs）、限定日费用（DDC）以及药品排序比（B/A）进行统计分析。结果 2014—2016南京地区34家医院质子泵抑制剂的销售金额逐年增长，以注射剂型为主，品种固定。注射用兰索拉唑（30 mg）、注射用泮托拉唑钠（40 mg）和奥美拉唑注射液（40 mg）的销售金额连续3年排名前3位，奥美拉唑肠溶胶囊（20 mg），兰索拉唑片（15 mg）和雷贝拉唑钠肠溶片（10 mg）的DDDs连续3年均排名前3位；注射剂型的DDC普遍高于口服剂型。B/A接近1.0的药物有泮托拉唑钠肠溶片（40 mg）、雷贝拉唑钠肠溶胶囊（10 mg）、泮托拉唑钠肠溶胶囊（20 mg）。结论 南京地区34家医院2014—2016年第1代质子泵抑制剂的使用仍在临床占主要地位，但其他新型质子泵抑制剂的使用也越来越广泛，使用基本合理。

Objective To analyze the use of proton pump inhibitors (PPIs) in 34 hospitals from Nanjing area from 2014 to 2016, so as to understand the clinical application trend and rationality of PPIs. Methods Specification, quantity, sales amount, defined daily doses (DDDs), defined daily cost (DDC), and drug sequence ratio of PPIs in 34 hospitals from Nanjing area from 2014 to 2016 were analyzed statistically. Results The sales amount of PPIs in 34 hospitals in Nanjing area increased year by year in the past three years, and the injection dosage forms were mainly used. The types of PPIs remained unchanged. Lansoprazole for injection (30 mg), Pantoprazole Sodium for injection (40 mg), and Omeprazole Injection (40 mg) were the top three in terms of sales amount for three consecutive years. DDDs of Omeprazole Enteric-coated Capsules (20 mg), Lansoprazole Tablets (15 mg), and Sodium Rabeprazole Enteric-coated Tablets (10 mg) ranked the top three for three consecutive years. DDC of PPIs in injection dosage forms was commonly higher than that of PPIs in oral dosage forms. B/A of Pantoprazole Sodium Enteric-Coated Tablets (40 mg), Rabeprazole Sodium Enteric-coated Capsules (10 mg), and Pantoprazole Sodium Enteric-Coated Capsules (20 mg) were close to 1.0. Conclusion The use of the first-generation PPIs from 2014 to 2016 in Nanjing area still occupies a major position in clinical practice, but other new PPIs are also more and more widely used, and their use is basically reasonable.